Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.52 |
| ▸ | GJB2 | P29033 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 3/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.45 |
| ▸ | CDC25B | P30305 | 5/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7564133 | 0.99 | SSTR1 (0.54) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7564138 | 0.99 | SSTR1 (0.54) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7770650 | 0.96 | GJB2 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7770653 | 0.96 | GJB2 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL9149963 | 0.96 | GJB2 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL9149969 | 0.96 | GJB2 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7563593 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2562480 | 0.92 | HTR1A (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13591465 | 0.92 | HTR1A (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13204990 | 0.92 | HTR1A (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930717-A | 1-Triazole ribose derivative and preparation method and application thereof | 上海泓博智源医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | SSTR1 4452/4885SSTR2 4263/4885SSTR4 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.